NCT05691361View on ClinicalTrials.gov

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

July 21, 2025

Study Completion Date

January 31, 2026

Conditions
Hereditary Angioedema
Interventions
DRUG

ADX-324

siRNA duplex oligonucleotide

DRUG

Placebo

saline

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research, Adelaide

Sponsors

Collaborators (1)

Avance Clinical Pty Ltd.
All Listed Sponsors
collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

ADARx Pharmaceuticals, Inc.

INDUSTRY